ScholarIQanswers from OpenAlex

Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy

PaperCitations, authors & open-access status

Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy have?

ScholarIQcitation count

Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy has 21 citations in the OpenAlex counts ScholarIQ stores.

When was Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy published?

ScholarIQyear

Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy has 2015 year in the ScholarIQ index.

What is the open-access status of Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy?

ScholarIQoa status

Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy has gold oa status in the ScholarIQ index.

What is the DOI of Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy?

ScholarIQdoi

The DOI for Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy is on the source record.

What is the PMID of Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy?

ScholarIQpmid

The PMID for Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy is on the source record.

What is the OpenAlex record for Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy?

ScholarIQopenalex

The OpenAlex for Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial